PainReform Ltd. (PRFX) Stock Forecast
PRFX analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $12.00 average of analyst targets
- Upside to target
- +1,435.7% from the latest close
- Next earnings
- —
- 52-week range
- $0.78 – $6.60
PRFX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PRFX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | $0.00 | $0.00 | $0.00 | — | — | — |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PRFX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
PRFX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PRFX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PRFX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PRFX beat in 7 of 12.
What analysts expect from PRFX
The average price target is $12.00, 1,435.7% above the latest close of $0.78. For 2026 the average estimate is $0.00 per share. PainReform beat the EPS estimate in 7 of the last 12 quarters.
Related: PRFX income statement, PRFX key metrics, PRFX chart. See the PRFX stock overview for the latest quote and news.
PRFX forecast FAQ
What is PainReform's price target?
The average analyst price target for PainReform is $12.00, 1,435.7% above the latest close of $0.78.
Does PainReform usually beat earnings estimates?
PainReform reported EPS at or above the analyst estimate in 7 of the last 12 quarters.